Site search- 2023.11.14IRAnnouncement of Issuance of Series 16 Moving Strike Warrants and Unsecured Bonds (Private Placement Bonds: PPB)（499KB）
- 2023.11.10IRFinancial Results for the Six Months ended September 30, 2023 [Japanese GAAP]（315KB）
- 2023.11.4PRBrightPath to Update the Preclinical Data of iPSC-derived CAR-iNKT at SITC 2023（162KB）
- 2023.11.4PRBrightPath to Update the Preclinical Data of HER2-CAR-T at SITC 2023（105KB）
- 2023.10.17PRBrightPath to Update the Preclinical Data of HER2-CAR-T and iPSC-derived CAR-iNKT at SITC 2023
- 2023.8.10IRBrightPath Announces Financial Results of First Quarter of FYE March 31, 2024 [Japanese GAAP]
- 2023.8.10IRFinancial Results for the Three Months ended June 30, 2023 [Japanese GAAP] (non-consolidated)
- 2023.5.12IRFinancial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
- 2023.5.2IRBrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）
- 2023.11.14IRAnnouncement of Issuance of Series 16 Moving Strike Warrants and Unsecured Bonds (Private Placement Bonds: PPB)（499KB）
- 2023.11.10IRFinancial Results for the Six Months ended September 30, 2023 [Japanese GAAP]（315KB）
- 2023.8.10IRBrightPath Announces Financial Results of First Quarter of FYE March 31, 2024 [Japanese GAAP]
- 2023.8.10IRFinancial Results for the Three Months ended June 30, 2023 [Japanese GAAP] (non-consolidated)
- 2023.5.12IRFinancial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
- 2023.5.2IRBrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）